2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.
Emerging treatment options in this space are all trial based. The newer generation of antiangiogenic therapies have similar efficacy but are less toxic. Hsieh says mTOR inhibitors are also being improved.
There is also excitement surrounding immunotherapy in this space. Emerging immunotherapies are similar to interleukin-2 and interferon but are more effective, more specific, and less toxic.
Related Content: